Skip to main content
Premium Trial:

Request an Annual Quote

CareDx Preliminary Q3 Revenues Up 57 Percent

NEW YORK – Transplant diagnostics company CareDx said on Wednesday after the close of the market that its preliminary third quarter revenues rose an estimated 57 percent year over year.

For the three months ended Sept. 30, revenues are expected to be approximately $53 million, up from $33.8 million in Q3 2019. Analysts are expecting revenues of $44.7 million for the quarter.

Testing revenues for the quarter are expected to be approximately $45.2 million, up from $28.2 million in the year-ago period. CareDx said it returned approximately 21,800 total AlloSure and AlloMap patient results during the quarter. Product revenues are expected to be $5.4 million, up from $4.2 million in Q3 2019. Digital & other revenues are expected to be $2.4 million, compared to $1.4 million in the year-ago quarter.

"Our strong third quarter performance was driven by this dedication and our commitment to lead in advancing transplantation, underscored by our surveillance solutions, AlloSure and AlloMap," CareDx Chairman and CEO Peter Maag said in a statement.

The Scan

Foxtail Millet Pangenome, Graph-Based Reference Genome

Researchers in Nature Genetics described their generation of a foxtail millet pangenome, which they say can help in crop trait improvement.

Protein Length Distribution Consistent Across Species

An analysis in Genome Biology compares the lengths of proteins across more than 2,300 species, finding similar length distributions.

Novel Genetic Loci Linked to Insulin Resistance in New Study

A team reports in Nature Genetics that it used glucose challenge test data to home in on candidate genes involved in GLUT4 expression or trafficking.

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.